Contact us

Address: Eftimie Murgu Square, no.2, 300041, Timişoara
Phone: +40256/494604
E-mail: buda.valentina@umft.ro

Staff of the University Clinic

Head of the University Clinic

📲 Phone: 0256/494604

📧 Email: buda.valentina@umft.ro

📃 Curriculum vitae

         

Members

📲 Phone: 0256/494604

📧 Email: narcisa.dinu@umft.ro

📃 Curriculum vitae

         

General presentation

Clinical pharmacy was part, until September 2021, of the Pharmacology – Clinical pharmacy Department of the Faculty of Pharmacy, a discipline led from its establishment (October 2000) until retirement, in 2020, by Mrs. Prof. Univ. Dr. Carmen Cristescu.

Since September 2021, the discipline of Clinical pharmacy has become an independent discipline, along with Pharmaceutical care and Communication in pharmacy, with the promotion to the position of associate professor of clinical pharmacist Valentina Buda (former member of the Discipline Pharmacology – Clinical pharmacy since 2010). From December 2023, it became a University Clinic, along with the change of the University Carta and the Organizational and Operating Regulations of the UMFVBT.

Clinical pharmacy is a modern pharmaceutical discipline that allows the 5th year student to integrate pharmaceutical and biomedical knowledge into the specific clinical context of the patient, thus acquiring a range of practical skills to respond in a timely and appropriate manner to the particular situation of the patient. The Clinical pharmacy is carried out during the first semester of the 5th year, having allocated 2 hours of course and 2 hours of practical works / clinical internships per week, at the headquarters of the discipline and in various medical departments within the hospitals. The information presented to the student has as essential purpose in his preparation in order to personalize the drug therapy, to prevent and combat the iatrogenic pathology, as well as to evaluate the therapeutic protocol from the point of view of the benefit / risk and benefit / cost ratio.

Clinical pharmacy is considered essential in the process of medical-pharmaceutical care, with the aim of increasing the quality of the therapeutic act, with the lowest costs for the medical system. 

The concept of Pharmaceutical care is a relatively new concept designed to continuously improve the use of medicines and maintain / increase the patient’s quality of life. It has been defined as the pharmacist’s commitment to take responsibility for the clinical achievement of the preventive, curative or palliative objectives of pharmacotherapy. Thus, the course of Pharmaceutical care aims to present and analyze the most common medical problems and conditions that require the intervention of the pharmacist: from the prevention of certain pathologies (osteoporosis, coronary heart disease, obesity, hypertension, diabetes, etc.), to the associated recommendation intestinal transit, osteoarthritis, chronic venous insufficiency, etc.), as well as therapeutic counseling (education) of patients. The Pharmaceutical care course takes place during the second semester of the last year of study, being a specialized course for the future pharmacist. 

Clinical pharmacy, along with Pharmaceutical care is, today, the substratum of the pharmacist profession, both for the pharmacist in the community pharmacy as well as for the hospital pharmacist. 

The Communication in pharmacy course aims to present the specific concepts of communication management in promoting health, techniques and skills of effective communication between pharmacist /pharmacy assistant-patient-physician. This course also aims to identify the most effective methods of educating the patient to improve their adherence to treatment and to better manage their own health problems.

The didactic activity of the university clinic:
– courses, practical works and clinical internships for undergraduate programs
– coordination of undergraduate final thesis
– postgraduate continuing education courses for pharmacists/pharmacy assistant/physicians
– coordination of Clinical Pharmacy specialization programme
– coordination of doctoral thesis 

University clinic research activity is based on the following:
– evaluation of the efficacy and safety of several medicines (e.g. antihypertensives, antipsychotics) or phytocompounds
– evaluation of the prescription and use of certain medicines (either in pediatrics, in the adult population or in the elderly) (appropriate/inappropriate prescribing)
– clinical and pre-clinical studies evaluating substances with pharmacological properties. 

Internships abroad:
– Clinical Pharmacy Internship – Universite Catholique de Louvain, Brussels, Belgium – under the coordination of: Anne Spinewine, Olivia Dalleur, Paul Tulkens
– Personalized Medicine Internship – Erasmus University Medical Center, Rotterdam, The Netherlands – coordinated by: Peter J. Van der Speak

Research projects

Project director:

  • PII-C4-TC-2016 / 16441-09 – The role of perindopril and candesartan in improving endothelial function in hypertensive patients. Period: 2016 (12 months), total financing: 22.500 RON 
  • 5DOC / 1425 / 03.02.2020 – A comprehensive in vitro and in vivo evaluation of Aronia melanocarpa (Michx.) Elliott standardized bio juice on blood pressure levels and endothelial damage. A prospective study. Period 2020 – 2022 (36 months), total funding: 30.000 EURO              

Project member:

  • PN-III-P1-1.1-TE-2016-1165 – UEFISCDI – Hyphenated and complementary instrumental techniques for the analysis, control and recovery of bioactive compounds used in hormone therapies (RECOTHER). Financing period 2018-2020 (24 months), Budget: 450.000 RON.
  • 3POSTDOC / 1238 / 30.01.2020 – Populi gemmae- a double gain for the pharmaceutical field: therapeutic potential and bio-source for green synthesis of silver nanoparticles, project director: conf. Univ. Dr. Corina Danciu, period 2020 – 2022 (36 months), total funding: 50.000 EURO
Discipline publications

University courses:   

  • Carmen Cristescu, Mirela Voicu, Maria Suciu, Liana Suciu, Valentina Buda. Clinical Pharmacy. Eurobit Publishing. 2015. ISBN 978-973-132-261-2               

Book chapters:

  • Valentina Buda, Minodora Andor, Diana Antal, Florina Ardelean, Ioana Zinuca Pavel, Cristina Dehelean, Codruta Soica, Roxana Folescu, Felicia Andrei, Corina Danciu. Cardioprotective effects of cultivated black chokeberries (Aronia spp.): traditional uses, phytochemistry and therapeutic effects. Natural Products – from bioactive molecules to human health. Ed:IntechOpen 2020, DOI: 10.5772/intechopen.92238, ISBN 978-1-83962-155-0, London, United Kingdom
  • Corina Danciu, Diana Antal, Stefana Avram, Valentina Buda, Ioana Zinuca Pavel, Daliana Minda, Florina Ardelean, Mirela Nicolov and Cristina Dehelean. Essential mineral elements: macronutrients and micronutrients from herbs in human health-phytochemicals. Plant sources and potential health benefits, Ed. Iman Ryan, Series: Plant Science Research and Practices, ISBN: 978-1-53615-478-8, Nova Science Publishers, Inc., New York, USA, 2019.

Choice tests book:

  • Simona Negreş, Cornel Chiriţă, Titica Maria Dogaru, Camil Eugen Vari, Carmen Cristescu, Cristina Mogoşan, Veronica Bild, …, Valentina Buda, … .Pharmacology grid tests. Medical Publishing House. 2020. 806 pages. ISBN 978-973-39-0878-4

Translations of chapters from international books:     

  • Barbara G. Wells, Joseph T. Dipiro, Terry L. Schwinghammer, Cecilz V. DiPiro. Manual of Pharmacotherapy. Prior Publishing. 2019. 1008 pages. ISBN 978-973-88039-3-0. The coordinator of the Romanian edition: Adina Popa 

Published papers (the most reprezentatives, a non exhaustive list):

  1. Romanescu M, Oprean C, Lombrea A, Badescu B, Teodor A, Constantin GD, Andor M, Folescu R, Muntean D, Danciu C, Dalleur O, Batrina SL, Cretu O, Buda VO. Current State of Knowledge Regarding WHO High Priority Pathogens—Resistance Mechanisms and Proposed Solutions through Candidates Such as Essential Oils: A Systematic Review. International Journal of Molecular Sciences. 2023; 24(11):9727. https://doi.org/10.3390/ijms24119727 ISI, impact factor 6/2022
  2. Lombrea A, Romanescu M, Jianu N, Andor M, Suciu M, Man DE, Danciu C, Dehelean CA, Buda V. Sex-Related Differences in the Pharmacological Response in SARS-CoV-2 Infection, Dyslipidemia, and Diabetes Mellitus: A Narrative Review. Pharmaceuticals. 2023; 16(6):853. https://doi.org/10.3390/ph16060853 ISI, impact factor 6/2022
  3. Buda V, Prelipcean A, Cozma D, Man DE, Negres S, Scurtu A, Suciu M, Andor M, Danciu C, Crisan S, Dehelean CA, Petrescu L, Rachieru C. An Up-to-Date Article Regarding Particularities of Drug Treatment in Patients with Chronic Heart Failure. J Clin Med. 2022 Apr 4;11(7):2020. doi: 10.3390/jcm11072020. ISI, impact factor 3.9/2022
  4. Romanescu M, Buda V*, Lombrea A, Andor M, Ledeti I, Suciu M, Danciu C, Dehelean CA, Dehelean L. Sex-Related Differences in Pharmacological Response to CNS Drugs: A Narrative Review. Journal of Personalized Medicine. 2022; 12(6):907. https://doi.org/10.3390/jpm12060907 ISI, impact factor 3.508/2021 
  5. Badescu B, Buda V*, Romanescu M, Lombrea A, Danciu C, Dalleur O, Dohou AM, Dumitrascu V, Cretu O, Licker M, Muntean D. Current State of Knowledge Regarding WHO Critical Priority Pathogens: Mechanisms of Resistance and Proposed Solutions through Candidates Such as Essential Oils. Plants (Basel). 2022 Jul 6;11(14):1789. doi: 10.3390/plants11141789. ISI, impact factor 4.50/2022
  6. Suciu M, Vlaia L, Boujneh E, Suciu L, Buda VO*, Jianu N, Vlaia V, Cristescu C. Prevalence and Determinants of Self-Medication Practices among Cardiovascular Patients from Béja, North West Tunisia: A Community-Pharmacy-Based Survey. Pharmacy. 2024; 12(2):68. https://doi.org/10.3390/pharmacy12020068 ISI, impact factor 2.2/2022
  7. Dohou AM, Buda VO, Yemoa LA, Anagonou S, Van Bambeke F, Van Hees T, Dossou FM, Dalleur O. Antibiotic Usage in Patients Having Undergone Caesarean Section: A Three-Level Study in Benin. Antibiotics (Basel). 2022;11(5):617. doi: 10.3390/antibiotics11050617. ISI, impact factor 4.8/2022
  8. Dohou AM, Buda VO, Anagonou S, Van Bambeke F, Van Hees T, Dossou FM, Dalleur O. Healthcare Professionals’ Knowledge and Beliefs on Antibiotic Prophylaxis in Cesarean Section: A Mixed-Methods Study in Benin. Antibiotics (Basel). 2022;11(7):872. doi: 10.3390/antibiotics11070872. ISI, impact factor 4.8/2022
  9. Buda V, Andor M, Tudor A, Cretu O, Cristescu C, Danciu C, Ledeti I, Crainiceanu Z, Onel M, Bordejevic DA, Tomescu MC, Suciu O, Petrescu L, Man DE. The plasma level of soluble endoglin in hypertensive patients undergoing long-term treatment with candesartan. Farmacia. 2022; 70(1):90-101, doi 31925/farmacia.2022.1.14, ISI, impact factor 1.6/2022
  10. Buda V, Prelipcean A, Cristescu C, Roja A, Dalleur O, Andor M, Danciu C, Ledeti A, Dehelean CA, Cretu O. Prescription Habits Related to Chronic Pathologies of Elderly People in Primary Care in the Western Part of Romania: Current Practices, International Recommendations, and Future Perspectives Regarding the Overuse and Misuse of Medicines. Int J Environ Res Public Health. 2021 Jul 1;18(13):7043. doi: 10.3390/ijerph18137043. ISI, impact factor 4.614/2021
  11. Nicolov M, Cocora M, Buda V, Danciu C, Duse AO, Watz C, Borcan F. Hydrosoluble and Liposoluble Vitamins: New Perspectives through ADMET Analysis. Medicina. 2021; 57(11):1204. https://doi.org/10.3390/medicina57111204 ISI, impact factor 2.948/2021
  12. Dehelean L, Marinescu I, Stovicek PO, Romoşan AM, Romoşan RŞ, Bálint R, Bucatoş BO, Ciobanu AVL, Bondrescu M, Marinescu D, Manea MM, Buda VO, Andor M, Ciobanu AM. Impairment of the cardiac ejection fraction by blocking dopamine D2 receptors induced by long-acting injectable antipsychotic treatment. Rom J Morphol Embryol. 2021 Apr-Jun;62(2):497-508. doi: 10.47162/RJME.62.2.16. PMID: 35024738. ISI, impact factor 0.833/2021
  13. Suciu L, Suciu M, Voicu M, Mureșan R, Pârv FV, Buda V, Cristescu C. Factors Influencing Adherence to Treatment and Quality of Life for a Group of Patients with Essential Hypertension in Romania. Patient Prefer Adherence. 2021 Feb 26;15:483-491. doi: 10.2147/PPA.S269119. ISI, impact factor 2.314/2021
  14. Buda V, Prelipcean A, Andor M, Dehelean L, Dalleur O, Buda S, Spatar L, Mabda MC, Suciu M, Danciu C, Tudor A, Petrescu L, Cristescu C. Potentially Inappropriate Prescriptions in Ambulatory Elderly Patients Living in Rural Areas of Romania Using STOPP/START (Version 2) Criteria. Clin Interv Aging. 2020; 15:407-417. doi:10.2147/CIA.S233270 ISI, impact factor 4.458/2020
  15. Buda V, Baul B, Andor M, et al. Solid State Stability and Kinetics of Degradation for Candesartan-Pure Compound and Pharmaceutical Formulation. Pharmaceutics. 2020;12(2):86. doi:10.3390/pharmaceutics12020086 ISI, impact factor 6.321/2020
  16. Buda V, Brezoiu AM, Berger D, Pavel IZ, Muntean D, Minda D, Dehelean CA, Soica C, Diaconeasa Z, Folescu R, Danciu C. Biological Evaluation of Black Chokeberry Extract Free and Embedded in Two Mesoporous Silica-Type Matrices. Pharmaceutics. 2020 Sep 1;12(9):838. doi: 10.3390/pharmaceutics12090838. PMID: 32882983; PMCID: PMC7558869. ISI, impact factor 6.321/2020
  17. Radu G, Luca C, Petrescu L, Bordejevic DA, Tomescu MC, Andor M, Citu I, Mavrea A, Buda V et al. The Predictive Value of Endothelial Inflammatory Markers in the Onset of Schizophrenia. Neuropsychiatr Dis Treat. 2020;16:545-555. doi:10.2147/NDT.S240349. ISI, impact factor 2.570/2020
  18. Dehelean L, Romosan AM, Andor M, Buda VO, Bredicean AC, Manea MM, Papaya I, Romosan RS. Clinical factors influencing antipshychotic choice, dose and augmentation in patients treated with long acting antipsychotics. Farmacia 2020; 68(1):35-41, DOI:31925/farmacia.2020.1.6. ISI, impact factor 1.433/2020
  19. Fecker R, Buda V, Alexa E, et al. Phytochemical and Biological Screening of Oenothera Biennis L. Hydroalcoholic Extract. Biomolecules. 2020;10(6):E818. Published 2020 May 26. doi:10.3390/biom10060818. ISI, impact factor 4.879/2020
  20. Suciu M, Suciu L, Vlaia L, Voicu M, Buda V, Dragan L, Andor M, Vlaia V, Cristescu C, Hirjau M. The prevalence of inappropriate use of NSAIDs by cardiovascular patients for musculoskeletal disorders. Farmacia. 2020; 68(4):628-639. https://doi.org/10.31925/farmacia.2020.4.7, ISI, impact factor 1.433/2020
  21. Radu G, Bordejevic DA, Buda V, Tomescu MC, Dragan I, Dehelean L, Cocos IL, Cheveresan A, Andor M. Cardiovascular risk factors for different types of psychiatric pathologies. A correlative study. Farmacia. 2020; 68(5): 835-842. https://doi.org/10.31925/farmacia.2020.5.9 ISI, impact factor 1.433/2020
  22. Andor M, Dehelean L, Romosan AM, Buda V, Radu G, Caruntu F, Bordejevic A, Manea MM, Papava I, Bredicean CA, Romosan RS, Tomescu M. A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication. Neuropsihiatric Disease and Treatment. 2019; 15:349-355. doi: 10.2147/NDT.S186892. ISI, factor de impact 2.157/2019
  23. Buda V, Andor M, Baibata DE, Cozlac R, Radu G, Coricovac D, Danciu C, Ledeti I, Cheveresan A, Nica C, Tuduce P, Tomescu MC. Decreased sEng plasma levels in hypertensive patients with endothelial dysfunction under chronic treatment with Perindopril. Drug Design Development and Therapy. 2019; 13:1915-1924, doi: 2147/DDDT.S186378. ISI, Impact factor: 3.216/2019.
  24. Suciu M, Suciu L, Vlaia V, Voicu M, Buda V, Dragan L, Andor M, Vlaia V, Cristescu C. Prevalence and the patterns of use of the non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol among the general population. Farmacia. 2019; 67(2):337-345, DOI:31925/farmacia.2019.2.20, ISI, impact factor 1.607/2019
  25. Buda V, Andor M, Cristescu C, Tomescu MC, Muntean DM, Baibata DE, Bordejevic DA, Danciu C, Dalleur O, Coricovac D, Crainiceanu Z, Tudor A, Ledeti I, Petrescu L. Thrombospondin-1 serum levels in hypertensive patients with endothelial dysfunction after one year of treatment with perindopril. Drug Design Development and Therapy. 2019; 13:3515-3526, DOI:2147/DDDT.S218428 , ISI, impact factor 3.216/2019
  26. Muntean D, Licker M, Alexa E, Popescu I, Jianu C, Buda V, Dehelean CA, Ghiulai R, Horhat F, Horhat D, Danciu C. Evaluation of essential oil obtained from Mentha x piperita L. against multidrug-resistant strains. Infection and drug resistance. 2019; 12:2905-2914, DOI:2147/IDR.S218141, ISI, impact factor: 2.984/2019
  27. Dehelean L, Andor M, Romosan AM, Manea MM, Romosan RS, Papava I, Bredicean AC, Buda VO, Tomescu MC. Pharmacological and disorder associated cardiovascular changes in patients with psychosis. A comparison between olazapine and risperidone. 2018; 66(1):129-134 ISI, factor de impact 2.228/2018
  28. Cristescu C, Negres S, Suciu M, Voicu A, Buda V, Suciu L, Proks M, Voicu M. Study regarding the parents’ use of self-medication among children under 12 years old. Farmacia. 2018; 66(5):811-819. DOI: 31925/farmacia.2018.5.10 ISI, impact factor 1.527/2018
  29. Danciu C, Muntean D, Alexa E, Farcas C, Oprean C, Zupko I, Bor A, Minda D, Proks M, Buda V*, Hancianu M, Cioanca O, Soica C, Popescu S, Dehelean CA. Phytochemical Characterization and Evaluation of the Antimicrobial, Antiproliferative and Pro-Apoptotic Potential of Ephedra alata Decne. Hydroalcoholic Extract against the MCF-7 Breast Cancer Cell Line. 2018;24(1). pii: E13. doi: 10.3390/molecules24010013. ISI, factor de impact 3.06/2018
  30. Buda V, Andor M, Petrescu L, Cristescu C, Baibata DE, Voicu M, Munteanu M, Citu I, Muntean C, Cretu O, Tomescu MC. Perindopril Induces TSP-1 Expression in Hypertensive Patients with Endothelial Dysfunction in Chronic Treatment. Int J Mol Sci.2017; 18(2). doi: 10.3390/ijms18020348.   ISI, factor de impact 3.687/2017
  31. Buda V, Andor M, Cristescu C, Voicu M, Cochera F, Tuduce P, Petrescu L, Tomescu MC. The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension. Ir J Med Sci.2017; 186(3):621-629. doi: 10.1007/s11845-017-1580-5. ISI, factor de impact 1.045/2017
  32. Buda V, Andor M, Cristescu C, Voicu M, Suciu L, Muntean C, Cretu O, Baibata DE, Gheorghiu CM, Tomescu MC. The influence of perindopril on PTX3 plasma levels in hypertensive patients with endothelial dysfunction. Farmacia. 2016; 64(3):382-389 ISI, factor de impact 1.348/2016